Loading patent…
AssigneeCivitas Therapeutics, Inc.
InventorsKevin D. Kee, Ernest D. Penachio, Abhijit Kamerkar, Michael M. Lipp, Richard P. Batycky
Estimating the term…
The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.
A capsule for use in an inhalation device filled with a dry powder comprising levodopa, a salt and a phospholipid and having a working density between about 0.02 to about 0.1 g/cm3, and containing a capsule shell comprising hydroxypropyl methylcellulose (HPMC) and titanium dioxide, and wherein said capsule emits more powder comprising levodopa upon actuation of the inhalation device as compared to a capsule that comprises HPMC and is free of titanium dioxide;
Dependencies are inferred from the claim text.